GeneDx Holdings (NASDAQ: WGS) saw its stock rise over 8% following a strong second-quarter earnings report that revealed nearly $103 million in revenue, a 49% year-over-year increase, driven by a 69% surge in exome and genome testing sales. This performance stood in stark contrast to the S&P 500’s modest 0.3% decline.
Want More Context? 🔎
Are XRP and Bitcoin's Dips Simply Normal Corrections or Signs of a Cooling Crypto Market?
Bitcoin (CRYPTO: BTC) and XRP (CRYPTO: XRP) have experienced significant pullbacks after a period of strong growth, with XRP dropping nearly 20% in one session and Bitcoin retreating after hitting a record high in July. Despite concerns that the summer rally might be over, these pullbacks are considered typical in a bull market, suggesting they are just temporary pauses rather than a sign of a trend reversal. Want More Context? 🔎
Read more